Why Pfizer's Post-COVID Future Looks Brighter Than Ever

Core Insights - Pfizer's stock has declined approximately 61% since late 2021, primarily due to falling sales of its COVID-19 products, Comirnaty and Paxlovid, which generated $36.8 billion in 2021 but saw sales drop to $945 million and $918 million respectively in the first half of 2025 [1][7] - Despite the decline in COVID-19 product sales, Pfizer's future appears promising due to significant investments in cancer drug development, particularly through its acquisition of Seagen [2][7] Group 1: COVID-19 Product Sales - Comirnaty sales fell to $945 million in the first half of 2025 from $36.8 billion in 2021 [1] - Paxlovid sales decreased by 60% year over year to $918 million [1] Group 2: Cancer Drug Development - Pfizer invested $43 billion in Seagen, enhancing its cancer treatment portfolio, including the successful drug Padcev, which saw a 38% increase in sales to an annualized $2.2 billion in Q2 [2][7] - Padcev's sales growth is supported by positive results from a clinical trial showing improved long-term survival rates for patients receiving the drug before and after surgery [3] - Elrexfio, another acquired treatment, has shown promising results, shrinking tumors in 97% of newly diagnosed patients, with potential peak sales exceeding $5 billion annually [4][5]